Investor News

Tissuemed gains CE approval for its new double-sided adhesive patch, read more…

Medtronic’s Mark Fletcher talks about the agreement with Tissuemed, watch video…

Tissuemed responds to Covidien’s withdrawal of Pleuraseal, read more…

Tissuemed announces Neuro/Spinal distribution agreement with Medtronic, read more…

Tissuemed’s Board

Paul Banner has been Tissuemed’s Chairman since 2007. He is an experienced Director with a background in Private Equity backed businesses and a successful track record. Paul is a Fellow of the Institute of Actuaries and has managed private equity and venture capital money, investing in mainly UK private companies with involvement through Board Director or Chairman roles.

Dr David Mandley joined Tissuemed’s board in 2008 and was appointed CEO in October 2011. David, who has a doctorate in chemistry, has been associated with Tissuemed since 1993 when he was involved in collaborative research at Loughborough University. He transferred to direct employment by Tissuemed in 2000.  David has played a key part in the development of the company’s Tissuebond bioadhesive technology. Prior to his appointment as Tissuemed’s CEO, David had responsibility for Quality Assurance, Regulatory Affairs and Clinical Development programmes.

Jeremy Sampson was appointed to the Tissuemed board in 2007.  Most recently he assumed the Deputy Chairman and CFO role in October 2011. Jeremy has dealt with substantial commercial transactions in addition to execution of corporate funding rounds in the medical devices sector. His wealth of dedicated experience is an asset for the company’s strategic as well as financial management.

Gordon Sutherland was appointed as a non-executive Director to the Board in October 2011. Gordon has worked in the healthcare industry for over 30 years and has held senior positions with Johnson & Johnson, ConvaTec-Bristol Myers Squibb, Baxter Biosurgery Europe, Gambro and is currently with Invacare SARL as Head of Europe.